Biotech Stocks At 52-Week Highs - RNXT +12%, BLSM, RVTY, ATRC, BFRI
Several biotech stocks hit 52-week highs on August 28, 2026. RenovoRx (RNXT) rose 12% to $1.68 after positive Phase 3 trial data. BlossomHill (BLSM) reached $20.61, with FDA Fast Track designation for BH-30643. AtriCure (ATRC) hit $49.98, reporting Q2 revenue of $153.6M. Biofrontera (BFRI) climbed to $1.61 with 32.9% product revenue growth. Revvity (RVTY) reached $130.07, raising full-year revenue guidance to $2.83B-$2.86B.
How this was made
The 30-second read
Why it matters
Collective positive catalysts suggest sector‑wide optimism, but each company’s upside is contingent on future data releases and regulatory outcomes.
Market read
Highlights a cluster of biotech stocks with strong near‑term catalysts, useful for traders seeking sector‑wide exposure or individual breakout opportunities.
What to watch
Liquidity constraints in small‑cap biotech could amplify volatility and reverse moves.
Background
The article aggregates several biotech and med‑tech companies that reached 52‑week highs on the same day, highlighting recent clinical, regulatory, and financial milestones.
Ticker impact
RenovoRx stock rose >12% to a 52‑week high after reporting Phase 3 trial data for its RenovoCath delivery system.
Potential continuation of rally if data are confirmed in upcoming topline release.
Trial results are early and topline data are still months away, limiting immediate certainty.
BlossomHill shares hit a 52‑week high after receiving FDA Fast Track designation for its lead candidate BH‑30643.
Likely short‑term upside as investors price in faster path to approval.
The designation is a catalyst, but commercial impact depends on later trial outcomes.
AtriCure stock climbed to a 52‑week high after reporting Q2 revenue of $153.6 M and full‑year guidance of $602‑$610 M.
Support for continued price gains if guidance holds up in upcoming quarters.
Guidance is forward‑looking; execution risk remains.
Biofrontera shares rose >6% to a 52‑week high after reporting Q2 product‑revenue growth of 32.9% and a narrowed loss.
Potential modest upside as the loss reduction trend continues.
Scale is small; price move may be limited to short‑term traders.
Revvity stock hit a 52‑week high after posting Q2 revenue of $730 M and raising full‑year guidance to $2.83‑$2.86 B.
Likely continued upward pressure if subsequent quarters meet guidance.
Guidance lift is meaningful, but market may price in expectations quickly.
Market effects
Biotech and med‑tech sectors gain momentum from multiple FDA and trial updates.
U.S. biotech equities see broad uplift, potentially lifting related ETFs.
Limited to investors focused on U.S. biotech; no immediate macro effect.
Counterpoint
Price spikes may be short‑lived if trial data fail to translate into approvals.
Key entities
- companyRenovoRx Inc.
Oncology drug‑delivery developer reporting Phase 3 trial data.
- companyBlossomHill Therapeutics Inc.
Rare‑cancer biotech receiving FDA Fast Track.
- companyAtriCure Inc.
Cardiac‑device maker posting revenue growth and guidance.
- companyBiofrontera Inc.
Dermatology biotech improving earnings.
- companyRevvity Inc.
Health‑science solutions firm raising revenue outlook.
